Development and Validation of An Immune Gene Set-Based Prognostic Signature in Cutaneous Melanoma

References

• Duan J , CuiL, ZhaoXet al. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis. JAMA Oncol.6(3), 375–384 (2019).
   Web of Science ®Google Scholar
• Robert C , SchachterJ, LongGVet al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med.372(26), 2521–2532 (2015).
   PubMed Web of Science ®Google Scholar
• Seidel JA , OtsukaA, KabashimaK. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front. Oncol.8, 86 (2018).
   PubMed Web of Science ®Google Scholar
• Hugo W , ZaretskyJM, SunLet al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell165(1), 35–44 (2016).
   PubMed Web of Science ®Google Scholar
• Tunger A , SommerU, WehnerRet al. The evolving landscape of biomarkers for anti-PD-1 or anti-PD-L1 therapy. J. Clin. Med.8(10), 1534 (2019).
   PubMed Web of Science ®Google Scholar
• Tumeh PC , HarviewCL, YearleyJHet al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature515(7528), 568–571 (2014).
   PubMed Web of Science ®Google Scholar
• Selitsky SR , MoseLE, SmithCCet al. Prognostic value of B cells in cutaneous melanoma. Genome Med.11(1), 36 (2019).
   PubMedGoogle Scholar
• Cancer Genome Atlas N . Genomic classification of cutaneous melanoma. Cell161(7), 1681–1696 (2015).
   PubMed Web of Science ®Google Scholar
• Yang S , LiuT, NanHet al. Comprehensive analysis of prognostic immune-related genes in the tumor microenvironment of cutaneous melanoma. J. Cell. Physiol.235(2), 1025–1035 (2020).
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Program . http://tcga-data.nci.nih.gov/tcga
   Google Scholar
• Jayawardana K , SchrammSJ, HayduLet al. Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information. Int. J. Cancer136(4), 863–874 (2015).
   PubMed Web of Science ®Google Scholar
• Cabrita R , LaussM, SannaAet al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature577(7791), 561–565 (2020).
   PubMed Web of Science ®Google Scholar
• Budden T , DaveyRJ, VilainREet al. Repair of UVB-induced DNA damage is reduced in melanoma due to low XPC and global genome repair. Oncotarget7(38), 60940–60953 (2016).
   PubMedGoogle Scholar
• Ascierto ML , Makohon-MooreA, LipsonEJet al. Transcriptional mechanisms of resistance to anti-PD-1 therapy. Clin. Cancer Res.23(12), 3168–3180 (2017).
   PubMed Web of Science ®Google Scholar
• Bioconductor . https://bioconductor.org/packages/release/bioc/html/limma.html
   Google Scholar
• He Y , JiangZ, ChenC, WangX. Classification of triple-negative breast cancers based on immunogenomic profiling. J. Exp. Clin. Cancer Res.37(1), 327 (2018).
   PubMedGoogle Scholar
• Jin W , ZhangY, LiuZ, CheZ, GaoM, PengH. Exploration of the molecular characteristics of the tumor–immune interaction and the development of an individualized immune prognostic signature for neuroblastoma. J. Cell. Physiol.236(1), 294–308 (2020).
   PubMed Web of Science ®Google Scholar
• Hänzelmann S , CasteloR, GuinneyJ. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics14(1), 7 (2013).
   PubMed Web of Science ®Google Scholar
• Yoshihara K , ShahmoradgoliM, MartinezEet al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun.4, 2612 (2013).
   PubMed Web of Science ®Google Scholar
• Estimate Project . https://sourceforge.net/projects/estimateproject/
   Google Scholar
• Gentles AJ , NewmanAM, LiuCLet al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med.21(8), 938–945 (2015).
   PubMed Web of Science ®Google Scholar
• Kanehisa M , FurumichiM, TanabeM, SatoY, MorishimaK. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res.45(D1), D353–D361 (2017).
   PubMed Web of Science ®Google Scholar
• Subramanian A , TamayoP, MoothaVKet al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA102(43), 15545–15550 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang J-X , SongW, ChenZ-Het al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol.14(13), 1295–1306 (2013).
   PubMed Web of Science ®Google Scholar
• TIDE . http://tide.dfci.harvard.edu/
   Google Scholar
• Jiang P , GuS, PanDet al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med.24(10), 1550–1558 (2018).
   PubMed Web of Science ®Google Scholar
• Balachandran VP , GonenM, SmithJJ, DematteoRP. Nomograms in oncology: more than meets the eye. Lancet Oncol.16(4), e173–e180 (2015).
   PubMed Web of Science ®Google Scholar
• IMMPORT . https://www.immport.org
   Google Scholar
• TIMER database. https://cistrome.shinyapps.io/timer/
   Google Scholar
• Hu J , XiaX, GorlickR, LiS. Induction of NKG2D ligand expression on tumor cells by CD8(+) T-cell engagement-mediated activation of nuclear factor-kappa B and p300/CBP-associated factor. Oncogene38(49), 7433–7446 (2019).
   PubMed Web of Science ®Google Scholar
• Kataoka TR , UeshimaC, HirataM, MinamiguchiS, HagaH. Killer immunoglobulin-like receptor 2DL4 (CD158d) regulates human mast cells both positively and negatively: possible roles in pregnancy and cancer metastasis. Int. J. Med. Sci.21(3), 954 (2020).
   Google Scholar
• Babar M , RyanAW, AndersonLAet al. Genes of the interleukin-18 pathway are associated with susceptibility to Barrett’s esophagus and esophageal adenocarcinoma. Am. J. Gastroenterol.107(9), 1331–1341 (2012).
   PubMed Web of Science ®Google Scholar
• Pugh J , Nemat-GorganiN, DjaoudZ, GuethleinLA, NormanPJ, ParhamP. In vitro education of human natural killer cells by KIR3DL1. Life Sci. Alliance2(6), e201900434 (2019).
   PubMed Web of Science ®Google Scholar
• Boudreau JE , GiglioF, GooleyTet al. KIR3DL1/HLA-B subtypes govern acute myelogenous leukemia relapse after hematopoietic cell transplantation. J. Clin. Oncol.35(20), 2268–2278 (2017).
   PubMed Web of Science ®Google Scholar
• Yoshida H , HunterCA. The immunobiology of interleukin-27. Annu. Rev. Immunol.33, 417–443 (2015).
   PubMed Web of Science ®Google Scholar
• Chihara N , MadiA, KondoTet al. Induction and transcriptional regulation of the co-inhibitory gene module in T cells. Nature558(7710), 454–459 (2018).
   PubMed Web of Science ®Google Scholar
• Achkar T , TarhiniAA. The use of immunotherapy in the treatment of melanoma. J. Hematol. Oncol.10(1), 88 (2017).
   PubMedGoogle Scholar
• Lipson EJ , VelculescuVE, PritchardTSet al. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J. Immunother. Cancer2(1), 42 (2014).
   PubMedGoogle Scholar
• Lucci A , HallCS, PatelSPet al. Circulating tumor cells and early relapse in node-positive melanoma. Clin. Cancer Res.26(8), 1886–1895 (2020).
   PubMed Web of Science ®Google Scholar
• Rad Pour S , PicoDe Coaña Y, DemorentinXMet al. Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood. J. Immunother. Cancer9(5), e002171 (2021).
   PubMed Web of Science ®Google Scholar
• Tonella L , PalaV, PontiRet al. Prognostic and predictive biomarkers in stage III melanoma: current insights and clinical implications. Int. J. Mol. Sci.22(9), 4561 (2021).
   PubMed Web of Science ®Google Scholar
• Zager JS , GastmanBR, LeachmanSet al. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer18(1), 130 (2018).
   PubMedGoogle Scholar
• Snyder A , MakarovV, MerghoubTet al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med.371(23), 2189–2199 (2014).
   PubMed Web of Science ®Google Scholar
• Gide TN , QuekC, MenziesAMet al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/Anti-CTLA-4 combined therapy. Cancer Cell35(2), 238–255 e236 (2019).
   PubMed Web of Science ®Google Scholar